Theralase Technologies Inc (CVE:TLT) reached a key milestone - striking a deal with the Princess Margaret Cancer Centre, part of the University Health Network (UHN), to carry out a Phase Ib clinical study for its laser technology for non-muscle invasive bladder cancer (NMIBC).
The study will be conducted by the Department of Urology at UHN, under the guidance of clinical principal investigator, Dr. Girish Kulkarni.
Theralase president and chief executive Roger Dumoulin-White told investors: "The execution of the CRA with UHN to conduct a Phase Ib clinical study for patients afflicted with NMIBC allows the ability to commence enrolling patients immediately upon Health Canada approval of the ITA, expected in late 2Q2016.
"The company looks forward to introducing this game changing technology to the world."
Dr Michael Jewett, uro-oncologist at UHN, added: "Theralase has completed numerous strategic milestones leading up to this Phase Ib clinical study and I have been very pleased with the speed and capability of the researchers to accomplish a great many tasks in a very short period of time."
Theralase scientific research has been validated through peer reviewed publications and supports a Phase Ib clinical study, pending approval by Health Canada of the Investigational Testing Authorization (ITA), for the medical laser used to activate the lead PDC, TLD-1433."